The Effect on Depressive Symptoms in ECF Residents With COPD

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effect of treatment with Advair Diskus on depression using the Cornell depression scale in COPD patients in the nursing home.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Valley Medical Research
• Treatments: Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Fluticasone-Salmeterol Drug Combination

Criteria

Inclusion Criteria:

• Adult men and women nursing home residents up to age 95

• Stated diagnosis of COPD or FEV1/FVC <0.7 or being treated with an anticholinergic

• Presence of depressive symptoms as measured on MDS 3.0 Section D SUM

• Free from conditions likely to be fatal within six months

• Able to read or understand English

• Able and willing to provide informed consent or has a guardian/LAR who can provide informed consent

Exclusion Criteria:

• Currently pregnant

• Unable to read and understand English

• Free from conditions likely to be fatal within six months

• Enrolled in hospice

• New treatment with antidepressant within the last 90 days.

• Current or recent use (within the last 90 days) of Advair Diskus

• Unwilling or unable to provide informed consent

• Expected to be discharged within 3 months